Compared to SII or other indicators, the differences in PSA levels between the prostate cancer group and the benign prostatic hyperplasia group are more pronounced, and PSA shows higher predictive efficacy for metastatic prostate cancer. Here, KLK3 is linked to benign prostatic hyperplasia.